XORTX Therapeutics (XRTX) Fundamental Analysis: Revenue, Earnings & Valuation

5.99 / 10

Netural

Fundamental rating is neutral with a 6/10 score. Strengths include low current‑liabilities ratio, solid interest‑coverage, and favorable PB‑ROE and Revenue‑MV. Caution stems from negative Asset‑MV and modest asset quality, yielding an overall balanced view.

Analysis Checks(9/10)

Revenue-MV

Value-0.11

Score3/3

Weight39.68%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value134.00

Score2/3

Weight0.55%

1M Return0.13%

Inventory turnover ratio

Value103.94

Score2/3

Weight-4.52%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value98.66

Score2/3

Weight1.53%

1M Return0.36%

PB-ROE

Value-0.27

Score3/3

Weight49.98%

1M Return9.18%

Long-term debt to working capital ratio (%)

Value0.01

Score3/3

Weight3.47%

1M Return0.87%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-4.60%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value177.16

Score2/3

Weight0.22%

1M Return0.05%

Cost of sales ratio (%)

Value64.41

Score2/3

Weight-4.35%

1M Return-1.13%

Asset-MV

Value-0.55

Score0/3

Weight18.04%

1M Return4.00%

Is XRTX fundamentally strong?

XRTX scores 5.99/10 on fundamentals and holds a Fair valuation at present. Backed by its -98.00% ROE, 0.00% net margin, -0.94 P/E ratio, 1.19 P/B ratio, and 51.30% earnings growth, these metrics solidify its Netural investment rating.